Daily Judi: Thursday, September 1, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
Sanofi won FDA approval for Xenpozyme, a therapeutic for a rare genetic pediatric disease, acid sphingomyelinase deficiency (ASMD). The FDA also awarded Sanofi a priority review voucher that it may sell to another pharmaceutical company. (Biopharma Dive)
Monkeypox, hepatitis, polio, COVID-19—speaking with infectious-disease expert, Azfar Chak, the Washington Post examines the summer of viruses.
Meanwhile, STAT details the significance of public health technology infrastructure in responding to crisis.
The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!
We also hope to see you this September 13-14, in Boston, for DPHARM: Disruptive Innovations to Advance Clinical Trials, walking distance from our North End headquarters.
“The final product that the client receives is fully configured to their trial, their forms, their workflow.”
–Jess, Program Manager
Judi empowers and enhances the world's clinical trial ecosystems. Our cloud-based platform has 110,000 users across 140 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.